2025
Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI
Shi A, Andrawis A, Biswas A, Wilson F, Obeid W, Philbrook H, Go A, Ikizler T, Siew E, Chinchilli V, Hsu C, Garg A, Reeves W, Prince D, Bhatraju P, Coca S, Liu K, Kimmel P, Kaufman J, Wurfel M, Himmelfarb J, Parikh C, Mansour S. Using vascular biomarkers to assess heart failure event risk in hospitalized patients with and without AKI. BMC Nephrology 2025, 26: 271. PMID: 40457292, PMCID: PMC12131712, DOI: 10.1186/s12882-025-04169-1.Peer-Reviewed Original ResearchConceptsArea under the curveRisk of HF eventsHeart failureHF eventsHospitalized patientsPrediction of HFVascular biomarkersClinical modelHigher risk of HF eventsPrediction of HF eventsLevels of injury markersRates of heart failureDormant phenotypeAssociated with higher riskCox regression analysisHeart failure eventsCardiovascular disease risk factorsPost-hospitalizationDisease risk factorsSerum creatinineAKI patientsStratify patientsInjury markersLung diseaseClinical centersCoronary Computed Angiography and Coronary Artery Calcium Score for Preoperative Cardiovascular Risk Stratification in Patients Undergoing Noncardiac Surgery
Kyriakoulis I, Kumar S, Lianos G, Schizas D, Kokkinidis D. Coronary Computed Angiography and Coronary Artery Calcium Score for Preoperative Cardiovascular Risk Stratification in Patients Undergoing Noncardiac Surgery. Journal Of Cardiovascular Development And Disease 2025, 12: 159. PMID: 40278217, PMCID: PMC12027494, DOI: 10.3390/jcdd12040159.Peer-Reviewed Original ResearchCoronary artery calcium scoreMajor adverse cardiovascular eventsPostoperative major adverse cardiovascular eventsArtery calcium scoreNoncardiac surgeryCalcium scoreRisk stratificationComputed angiographySeverity of coronary artery diseasePreoperative imaging protocolRisk evaluation of patientsPreoperative risk stratificationHigh-risk patientsEvaluation of patientsInfluence surgical decisionsAdverse cardiovascular eventsCoronary artery diseaseCardiovascular risk stratificationPerioperative risk predictionSuperior prognostic performanceStratify patientsAnatomical assessmentSurgical decisionCardiovascular eventsPrognostic performance16 Resource Allocation: Costs and Length of Stay for Non-Burn Patient in Burn Center
Usman M, Savetamal A. 16 Resource Allocation: Costs and Length of Stay for Non-Burn Patient in Burn Center. Journal Of Burn Care & Research 2025, 46: s13-s14. PMCID: PMC11958293, DOI: 10.1093/jbcr/iraf019.016.Peer-Reviewed Original ResearchNon-burn patientsLength of stayDiverse patient populationsBurn patientsPatient populationBurn centerNecrotizing soft tissue infectionStevens-Johnson syndrome/toxic epidermal necrolysisSoft tissue infectionsEnhance patient outcomesHigh-level careElectronic medical recordsBurn care settingNon-burn injuryHigh-quality treatmentSoft tissue injuriesCare settingsSoft tissue pathologyCare efficiencyTissue infectionsStratify patientsHospital stayFournier's gangreneEpidermal necrolysisRetrospective analysis
2024
Association of Physician Certification and Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion
Vora A, Pereira L, Du C, Tan Z, Huang C, Friedman D, Wang Y, Faridi K, Lakkireddy D, Zimmerman S, Higgins A, Kapadia S, Curtis J, Freeman J. Association of Physician Certification and Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. JACC Cardiovascular Interventions 2024, 18: 591-602. PMID: 39474982, DOI: 10.1016/j.jcin.2024.10.020.Peer-Reviewed Original ResearchPhysician certificationAppendage occlusionAdverse eventsPercutaneous left atrial appendage occlusionLong-term oral anticoagulationDischarged patientsMultivariate Cox proportional hazards regression analysisRate of procedural complicationsLeft atrial appendage occlusionCox proportional hazards regression analysisProportional hazards regression analysisRisk of adverse eventsHazards regression analysisIn-Hospital DeathOral anticoagulantsWatchman FLXNo significant differenceLAAO devicesProcedural complicationsStratify patientsIntracardiac echocardiographyAtrial fibrillationEligible patientsIdentified patientsMultivariable adjustmentPredictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
Dutta R, Thibaud S, Leshchenko V, Ram M, Melnekoff D, Bhalla S, Restrepo P, Gupta V, Barwick B, Newman S, McCafferty J, Hantash F, Nooka A, Cho H, Richard S, Rodriguez C, Rossi A, Sanchez L, Chari A, Boise L, Jagannath S, Richter J, Parekh S, Laganà A. Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma. Blood Neoplasia 2024, 1: 100049. PMID: 40552134, PMCID: PMC12182838, DOI: 10.1016/j.bneo.2024.100049.Peer-Reviewed Original ResearchCyclin-dependent kinase 7Progression-free survivalMultiple myelomaAnalysis of RNA-seq dataMM cellsTherapeutic strategiesPatients treated with venetoclaxCDK7 inhibitor THZ1Overcome venetoclax resistanceRNA-seq dataSix-gene signaturePredictors of responseChromosome 1q gainPersonalized therapeutic strategiesDevelopment of personalized therapeutic strategiesInduce cell deathMarkers of sensitivityBCL2 inhibitorsCDK7 inhibitionMCL1 genePrognostic importanceStratify patientsCyclin-dependentMCL1 levelsPatient populationAssociation between Preoperative Neutrophil-lymphocyte Ratio and All-cause Mortality in Patients Treated with Thoracic Endovascular Aortic Repair for Degenerative Thoracic Aortic Aneurysm
Kano M, Nishibe T, Dardik A, Iwahashi T, Nakano Y, Shimahara Y. Association between Preoperative Neutrophil-lymphocyte Ratio and All-cause Mortality in Patients Treated with Thoracic Endovascular Aortic Repair for Degenerative Thoracic Aortic Aneurysm. Annals Of Vascular Surgery 2024, 110: 255-264. PMID: 39341560, DOI: 10.1016/j.avsg.2024.07.110.Peer-Reviewed Original ResearchThoracic endovascular aortic repairPatients treated with thoracic endovascular aortic repairDegenerative thoracic aortic aneurysmsPreoperative neutrophil-lymphocyte ratioNeutrophil-lymphocyte ratioThoracic aortic aneurysmAll-Cause MortalityEndovascular aortic repairAortic repairAortic aneurysmCut-off values of neutrophil-lymphocyte ratioOptimal cut-off values of neutrophil-lymphocyte ratioElevated preoperative neutrophil-lymphocyte ratioOverall mortalityValue of neutrophil-lymphocyte ratioOptimal cut-off valueAbsolute lymphocyte countAbsolute neutrophil countRisk of overall mortalityLikelihood of all-cause mortalityReceiver operating characteristic curveIschemic heart diseaseLymphocyte countStratify patientsNeutrophil countRisk prediction for clonal cytopenia: multicenter real-world evidence
Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, PMCID: PMC11561536, DOI: 10.1182/blood.2024024756.Peer-Reviewed Original ResearchMyeloid neoplasmsIncidence of MNClonal cytopeniaCumulative incidencePlatelet count <High-risk mutationsCox proportional hazards modelsVariant allele fractionProportional hazards modelClinical trial designCCUS patientsStratify patientsGray's testC-indexDisease entityRisk groupsCytopeniasAllele fractionSomatic mutationsRisk factorsHigh riskNatural historyRisk scoreHazards modelPatientsTumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 35: 73-83. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular Carcinoma ImmunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting Overall SurvivalCox regression modelsSurvival benefitStratify patientsMRI pre-The Predictive Value of Qanadli and Miller Index Scores in Patients with Intermediate-High–Risk and High-Risk Pulmonary Emboli Undergoing Aspiration Thrombectomy
Fish A, Knight E, Mutonga M, Moulton J, Gathagan R, Andreca M, Sare A, Cornman-Homonoff J. The Predictive Value of Qanadli and Miller Index Scores in Patients with Intermediate-High–Risk and High-Risk Pulmonary Emboli Undergoing Aspiration Thrombectomy. Journal Of Vascular And Interventional Radiology 2024, 35: 1457-1463. PMID: 38969337, DOI: 10.1016/j.jvir.2024.06.031.Peer-Reviewed Original ResearchPulmonary artery pressureIntensive care unitMiller scoreHigh-risk patientsArterial pressureInstitutional review boardPulmonary pressureClot burdenB-type natriuretic peptideIntensive care unit length of stayAssociated with ICU lengthIntensive care unit lengthLength of stayFlowTriever SystemConsecutive patientsEchocardiographic findingsPulmonary emboliCreatinine levelsPulmonary embolismNatriuretic peptideStratify patientsRetrospective studyClinical outcomesAspiration thrombectomyICU lengthOncogenic composite mutations can be predicted by co‐mutations and their chromosomal location
Küçükosmanoglu A, van der Borden C, de Boer L, Verhaak R, Noske D, Wurdinger T, Radonic T, Westerman B. Oncogenic composite mutations can be predicted by co‐mutations and their chromosomal location. Molecular Oncology 2024, 18: 2407-2422. PMID: 38757376, PMCID: PMC11459034, DOI: 10.1002/1878-0261.13636.Peer-Reviewed Original ResearchComposite mutationCo-mutationsMutation-specific drugsCell line dataChromosomal locationSub-clonal populationsGenetic heterogeneitySub-clonesTherapy resistanceSelection pressureGenetic eventsStratify patientsKRAS geneResistance-causing mutationsCancer patientsBiopsy samplesMutationsPatientsGenesPrecision medicineTherapyRiskChromosomeBiopsyBRAFP695 Untargeted proteomics analysis of baseline serum samples prior to biologic therapy initiation
Rauch M, Laponogov I, van Welsen I, Quinn A, Joustra V, Paulich H, Perez B, Ramkisoen R, Noble A, Satsangi J, D’Haens G, Williamson A, Veselkov K, van 't Wout A. P695 Untargeted proteomics analysis of baseline serum samples prior to biologic therapy initiation. Journal Of Crohn's And Colitis 2024, 18: i1306-i1307. DOI: 10.1093/ecco-jcc/jjad212.0825.Peer-Reviewed Original ResearchAnti-TNFa treatmentAnti-TNFaSerum proteomic profilesTreatment outcomesCrohn's diseaseTreatment responseNon-respondersCD patientsBiological drugsModerate to severe CDSerum collectionSustained clinical responseFirst-line therapyBaseline serum samplesProteomic profilingBiobanked serum samplesBiologic treatment outcomesSevere CD patientsSerum samplesBiologic treatment responseStandard of careSerum proteomic analysisClinical responseStratify patientsSevere CD
2023
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile
Grajales V, Contieri R, Tan W, Flores M, Schultz M, Pinochet R, Bustamante A, Kamat A, Fernández M. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. Bladder Cancer 2023, 9: 327-334. PMID: 38994240, PMCID: PMC11165921, DOI: 10.3233/blc-230047.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBacillus Calmette-GuerinBacillus Calmette-Guerin treatmentHR-NMIBC patientsInvasive bladder cancerOncological outcomesHigh riskBladder cancerHigh-risk non-muscle invasive bladder cancerPatients treated with bacillus Calmette-GuerinAdjuvant bacillus Calmette-GuerinBacillus Calmette-Guerin instillationsFull doseFD groupMultivariate Cox regression modelCalculate survival estimatesReduced-dose regimensMedian Follow-UpRecurrence free rateKaplan-Meier methodReduced toxicity profileCox regression modelsHR-NMIBCStratify patientsRetrospective study
2022
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
Chan J, Zaidi S, Love J, Zhao J, Setty M, Wadosky K, Gopalan A, Choo Z, Persad S, Choi J, LaClair J, Lawrence K, Chaudhary O, Xu T, Masilionis I, Linkov I, Wang S, Lee C, Barlas A, Morris M, Mazutis L, Chaligne R, Chen Y, Goodrich D, Karthaus W, Pe'er D, Sawyers C. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 2022, 377: 1180-1191. PMID: 35981096, PMCID: PMC9653178, DOI: 10.1126/science.abn0478.Peer-Reviewed Original ResearchConceptsFibroblast growth factor receptorProstate cancerLineage plasticityJanus kinaseGenetically engineered mouse modelsCastration-resistant diseaseFibroblast growth factor receptor signalingTumor cell statesGrowth factor receptorSingle-cell analysisMetastatic diseaseStratify patientsIncreased JAK/STATAntiandrogen resistanceEpithelial populationsDrug resistanceFactor receptorClinical trialsInhibitor treatmentMouse modelInflammatory signalingGene expressionCell statesMurine organoidsMolecular mechanisms
2021
Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study
Mahmud N, Fricker Z, Lewis JD, Taddei TH, Goldberg DS, Kaplan DE. Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Clinical Gastroenterology And Hepatology 2021, 20: e1121-e1134. PMID: 34246794, PMCID: PMC8741885, DOI: 10.1016/j.cgh.2021.06.050.Peer-Reviewed Original ResearchConceptsLiver diseasePostoperative decompensationPostoperative mortalityPostoperative infectionRisk scoreAlcohol-related liver diseaseEnd-stage liver diseaseMayo risk scoreSurgical risk scoresData of patientsMultivariable logistic regressionVeterans Health AdministrationRange of surgeryRisk prediction modelCirrhosis decompensationPugh scoreChild-TurcottePostoperative complicationsCohort studyPostoperative dayRetrospective studyStratify patientsVeteran outcomesDecompensationExcellent calibrationCharacterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging?
Bikkasani K, Qin Q, Zhong X, Lin J, Galsky M, Oh W, Tsao C. Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging? Clinical Genitourinary Cancer 2021, 19: e346-e351. PMID: 34011488, DOI: 10.1016/j.clgc.2021.04.003.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerProstate-specific antigen levelProstate-specific antigenCastration-resistant prostate cancerProstate cancerClinical outcomesDiagnosis of metastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancer patientsAssociated with lower Gleason scoreSingle-institution databaseHigher PSA levelsInstitutional review board approvalLow Gleason scoreClinical characteristics of diseaseReview board approvalMolecular phenotypic differencesAssociated with lower ratesDiagnosis to deathGenitourinary cancer patientsPSA levelsGleason scoreAntigen levelsPredictive biomarkersStratify patientsClinical characteristicsImpact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu Y, Biswas D, Swanton C. Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars In Cancer Biology 2021, 84: 89-102. PMID: 33631295, PMCID: PMC9253787, DOI: 10.1016/j.semcancer.2021.02.013.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitor therapyCheckpoint inhibitorsIntratumour heterogeneityImmune surveillancePatient's response to immune checkpoint inhibitorsResponse to immune checkpoint inhibitorsCheckpoint inhibitor responseProportion of patientsStandard of carePredictive biomarkersStratify patientsImmune evasionDiagnostic accuracyInhibitor responseImmune systemMechanisms of genetic instabilityPatientsGenetic instabilityCancer evolutionTherapyCancerSurveillanceInhibitorsIntratumour“3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer
An O, Song Y, Ke X, So J, Sundar R, Yang H, Rha S, Lee M, Tay S, Ong X, Tan A, Ng M, Tantoso E, Chen L, Tan P, Yong W, Consortium S. “3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer. Cancer Research 2021, 81: 2788-2798. PMID: 33558338, DOI: 10.1158/0008-5472.can-20-2872.Peer-Reviewed Original ResearchConceptsAdvanced gastric cancerRNA editingRNA editing signaturesEditing levelsGastric cancerRNA editing eventsHigher editing levelsAdenosine-to-inosineRNA editing analysisGastric cancer cell linesPredictive biomarkersStratify patientsLevels of editingGene expression profilesPredicting response to chemotherapyEditing sitesEditing eventsMolecular subtypes of gastric cancerCancer cell linesPlatinum-based chemotherapyMetastatic gastric cancerSubtypes of gastric cancerCancer Genome AtlasFirst-line therapyResponse to chemotherapy
2020
A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL
Li X, Jemaa S, Carano R, Bengtsson T, Paulson J, Jansen G, Nielsen T, Hibar D. A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL. Blood 2020, 136: 28. DOI: 10.1182/blood-2020-134877.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaProgression-free survivalCurrent equity holderInternational Prognostic IndexFDG-PET scansProgression-free survival probabilityLow-risk groupHigh-risk groupBaseline FDG-PET scanHigh-risk patientsPredicting high-risk patientsFollicular lymphomaFL patientsPrognostic performanceF. Hoffmann-La RocheRadiomic featuresCHOP chemotherapyGALLIUM studyStratify patientsDe novo diffuse large B-cell lymphomaDLBCL populationDiffuse large B-cell lymphoma patientsHigh-risk patient subpopulationsInternational Prognostic Index modelLarge B-cell lymphoma
2019
Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.
Bikkasani K, Qin Q, Lin J, Galsky M, Liaw B, Oh W, Tsao C. Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer. Journal Of Clinical Oncology 2019, 37: 184-184. DOI: 10.1200/jco.2019.37.7_suppl.184.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerProstate specific antigenCastration-resistant prostate cancerProstate cancerClinical characteristicsDiagnosis of metastatic castration-resistant prostate cancerBurden of metastatic diseaseHigher PSA levelsInstitution retrospective studyIRB-approved databaseClinical characteristics of diseaseData of patientsGU cancer patientsMount Sinai HospitalCastration resistancePSA levelsMetastatic diseaseOverall survivalPredictive biomarkersStratify patientsRetrospective studySpecific antigenTreatment responsePC patientsCancer patients
2018
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial
Yong W, Rha S, Tan I, Choo S, Syn N, Koh V, Tan S, Asuncion B, Sundar R, So J, Shabbir A, Tan C, Kim H, Jung M, Chung H, Ng M, Tai D, Lee M, Wu J, Yeoh K, Tan P, Consortium O. Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial. Clinical Cancer Research 2018, 24: 5272-5281. PMID: 30045931, DOI: 10.1158/1078-0432.ccr-18-0193.Peer-Reviewed Original ResearchConceptsGenomic classifierManagement of advanced gastric cancerGastric cancerS-1 regimenOpen-label phaseAdvanced gastric cancerGastric cancer chemotherapySensitivity to oxaliplatinTreated with cisplatinTumor gene expressionMedian turnaround timeTreated with SPGene expression signaturesSOX chemotherapyPatient tumorsTreatment stratificationStratify patientsMetabolic signaturesChemotherapyGene expression profilesOxaliplatinPatientsCancer chemotherapyPredictive valueResponse rate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply